Limonoid

Limonoids: A Comprehensive Reference

1. Identity and Chemical Classification

Nomenclature and Taxonomy

Limonoids are heavily oxygenated, modified triterpenes dominant in the Meliaceae and Rutaceae plant families. The term "limonoid" is derived from limonin, which was first identified as the bitter constituent of Citrus seeds in 1841. The term "limonoid" was given after limonin, the first bitter component identified in citrus seeds. More precisely, citrus limonoids are tetranortriterpenoid compounds mainly found in oranges, lemons, grapefruits, and other fruits of Citrus.

Limonoids occur naturally only in plant species of the Rutaceae and Meliaceae plant families. They are highly oxygenated modified triterpenes that are biosynthesized from the acetate–mevalonate pathway in citrus fruits. More than 300 limonoids have been isolated and they are described as more abundant and diverse in the Meliaceae family than in any other family.

Principal Natural Sources

Citrus limonoids (CLs) are a group of highly oxygenated terpenoid secondary metabolites found mostly in the seeds, fruits and peel tissues of citrus fruits such as lemons, limes, oranges, pumellos, grapefruits, bergamots, and mandarins. Limonoids are widely distributed in many Citrus fruits such as sweet orange (Citrus sinensis), lemon (Citrus limon), grapefruit (Citrus paradisi), lime (Citrus aurantiifolia), sour orange (Citrus aurantium), and pummelo (Citrus maxima).

Beyond citrus, limonoids are extensively found in the Meliaceae (mahogany) family. Neem (Azadirachta indica A. Juss) is one of the most versatile medicinal plants, widely distributed in the Indian subcontinent. Neem is a rich source of limonoids that are endowed with potent medicinal properties, predominantly antioxidant, anti-inflammatory, and anticancer activities. The first limonoid compound named gedunin was isolated from the wood of the West African plant Entandrophragma angolense, and its chemical structure was identified by comparison with limonin (Goerlich, 1960).

Key Individual Compounds

Limonin, the first characterized compound of this group of phytochemicals, has been known as a constituent of citrus since 1841. It was isolated from navel orange juice in 1938 and shown to be the bitter principle in navel orange juice in 1949. Limonin's chemical composition is C₂₆H₃₀O₈ with a molecular weight of 470.

Citrus fruits contain approximately 36 limonoid aglycones and 17 limonoid glucosides. Major citrus species accumulate limonin, nomilin, obacunone, and deacetylnomilin. In seeds, all seeds contained 17-β-D-glucopyranosides of limonin, nomilin, obacunone, deacetylnomilin, nomilinic acid and deacetylnomilinic acid. The total limonoid glucoside content ranged from 0.31 to 0.87% of the dry weight, and the concentration of nomilin glucoside was highest among the glucosides found in the seeds.

Lemon seeds were the most abundant source of limonoids, with obacunone recording the highest amount, followed by ichangin, deacetylnomilin, limonin, and nomilin. Lemon peels and pulp contained two components of limonoids, namely ichangin and obacunone, while lemon juice only had obacunone.

In neem and related Meliaceae, the most important individual limonoids include: azadirachtin, gedunin, and nimbolide, which are more extensively investigated relative to other neem limonoids.

Aglycone vs. Glucoside Forms

Limonoid aglycones that cause bitterness in numerous citrus fruits are converted into tasteless limonoid glucosides during fruit maturation. Soluble limonin glucoside is the predominant limonoid glucoside present in citrus juices, and it occurs at an amount twice that of the other limonoid glucosides combined. Limonoid glucosyltransferase (LGT) is the only single regulatory enzyme that is able to convert all limonoid aglycones such as nomilin, obacunone, and ichangin present in Citrus spp. to their respective glucosides, in addition to limonoate A-ring lactone (LARL) to limonin glucopyranoside.

Biosynthesis

Nomilin, the precursor and one of the major limonoids, is a triterpenoid. All kinds of limonoids are produced in the limonoids biosynthetic pathway via oxidization, isomerization, methylation, acetylation, and hydrolyzation of nomilin. The discovery of non-bitter limonoid glucosides and identification of the limonoid glucosyltransferase gene (LGT) responsible for converting limonoid aglycones into corresponding non-bitter limonoid glucosides was the most important breakthrough in understanding naturally occurring limonoid debittering processing.

Common Forms and Preparations

Limonoids are encountered in dietary and supplement contexts in several forms: as constituents of fresh citrus juice; as seed extracts (particularly from citrus seeds); as standardized extracts (aglycone or glucoside fractions); and, in the case of neem, as seed oil, leaf powder, and bark extracts. Each time we bite into a citrus slice or drink a glass of orange juice, our bodies can readily access a limonoid called limonin. The team (USDA ARS) was the first to show limonin's "bioavailability." The body derives limonin from a parent compound—limonin glucoside—that is present in citrus and citrus juices in about the same amount as vitamin C.

2. Traditional and Historical Use

Citrus and Rutaceae Traditions

The citrus limonoids are a rare natural compound group that has been thoroughly investigated on their biochemical nature, biological functions, food applications, importance in plant physiology, relationship in different plant species and cultivars, by-product recovery, and commercial applications. The historical use of limonoids as isolated compounds per se is limited, as traditional practitioners used whole citrus fruits, seeds, and peels without knowledge of their individual phytochemical constituents. However, the plants containing these compounds were central to many traditional medical systems. Oranges and lemons are considered potential sources of antioxidant agents scavenging free radicals and preventing their degenerative effects because of polyphenols, flavonoids, limonoids, carotenoids, and vitamin C.

Citrus fruits and their by-products have been used for centuries across Mediterranean, Middle Eastern, and Asian cultures. The bitter seeds and peels of citrus—the parts richest in limonoid aglycones—were employed in folk remedies and traditional pharmacopoeias for a range of purposes, including digestive complaints, fevers, and skin conditions. Early formal recognition of limonin's chemical existence dates to 1841 in European botanical and chemical literature.

Neem (Azadirachta indica) Tradition

Azadirachta indica (Neem) is a tree cultivated in the Indian subcontinent for around 4500 years owing to its medicinal and pesticidal significance due to its potential phytochemical ingredients, and has traditionally been used as folk medicine to treat ailments and as an agrochemical. Various parts of the neem tree, including leaves, flowers, fruits, seeds and bark, find extensive use in traditional systems of medicine (e.g., Ayurveda, Unani and Siddha) for treating various human diseases.

It has been widely utilized in Ayurveda, Unani, and Homeopathic treatments and has gained significant attention in modern medicine. Traditionally, neem leaves, flowers, seeds, fruits, roots, twigs, and bark have been used to treat fever, infection, skin conditions, and dental problems. The neem leaf is commonly and historically used in medicine to treat a variety of illnesses such as eye disorders, nose bleeding, loss of appetite, and liver problems. Because of its various pharmacological and therapeutic effects, it is included in the Ayurvedic pharmacopoeia.

Neem has been extensively used in Ayurveda, Unani, and Homeopathic medicines worldwide, especially in the Indian subcontinent, in the treatment and prevention of various diseases. The chemical and biological analysis of Azadirachta indica (Neem) discovered the existence of many bioactive substances in various plant parts, including limonoids (azadirachtin, nimbin and nimbidin), flavonoids (quercetin, catechin), phenolic compounds (gallotannins and ellagic acid), alkaloids and sulfur compounds.

Meliaceae Family (Mahogany and Related Trees)

Based on available data published between 2000 and 2020, documented limonoid bioactivities in the genus Khaya include anticancer, antimalarial, hepatoprotection, anti-inflammatory, neuroprotection, antimicrobial, antifungal, and antifeedant activities. The study revealed K. senegalensis as the most well-researched species with the most prominent biological activities and traditional uses in the genus. Pharmacological investigations carried out on limonoids isolated from different plant parts in the genus provided empirical support for some of its ethnomedicinal uses, mainly in treating malaria, fever, liver problems, microbial infections, and nervous disorders.

3. Key Constituents and Active Compounds

Citrus Limonoids

The primary biologically active citrus limonoids identified in research include:

• Limonin — the prototypical and most studied aglycone. Limonin is a natural tetracyclic triterpenoid compound that widely exists in Euodia rutaecarpa (Juss.) Benth., Phellodendron chinense Schneid., and Coptis chinensis Franch.
• Nomilin — the direct biosynthetic precursor of many other citrus limonoids. Nomilin is characterized by a seven-membered oxepine ring and may be considered as the product of an acetate equivalent addition to the structure of obacunone.
• Obacunone — also a major aglycone in citrus seeds.
• Limonin glucoside — the predominant water-soluble form in citrus juices.
• Deacetylnomilin, nomilinic acid, ichangin — additional aglycones and their corresponding glucosides.

Neem (Meliaceae) Limonoids

• Azadirachtin — a limonoid chiefly in seeds, the major antifeedant and insect growth regulator.
• Gedunin — several biological activities have been attributed to gedunin, including antibacterial, insecticidal, antimalarial, antiallergic, anti-inflammatory, anticancer, and neuroprotective effects. The discovery of gedunin as a heat shock protein (Hsp) inhibitor represented a very important landmark for its application as a biological therapeutic agent.
• Nimbolide, nimbin, nimbidin — additional neem limonoids with documented pharmacological activities.

Structural Chemistry

Nature gave a formidable representation in developing limonoid structures. The variety and complexity of scaffolds found in the limonoid family constitute the foundation for the wide range of biological activities shown by these compounds and represent a challenge for researchers who want to study structure–activity relationships (SAR). Overall, the diversification of citrus limonoids mostly occurs in the A and B rings along with different oxidation levels, while the D ring is either opened or lactonized.

Changes in the A ring of the limonoid nucleus can lead to a loss of anticancer activity, whereas changes in the D ring can be tolerated without any apparent loss of biological activity.

4. Established Mechanisms of Action

Phase II Enzyme Induction (Chemopreventive Mechanism)

One of the most replicated mechanistic findings for citrus limonoids is the induction of phase II detoxifying enzymes. One significant mechanism by which chemoprevention may be accomplished is by the induction of the activity of phase II detoxifying enzymes by bioactive components of fruits and vegetables. Among these detoxifying enzymes are glutathione S-transferase (GST) and NAD(P)H: quinone reductase (QR). GST isoenzymes are thought to play a crucial physiological role in the initial stages of detoxification of various xenobiotics including alkylating agents. Generally, an increase in the activity of GST enhances the ability of an organism to detoxify numerous potentially harmful xenobiotics. It has been reported that substances that increase the activity of GST can be potential chemopreventive agents with the ability to inhibit chemically induced cancer formation.

The presence of the furan moiety is thought to be responsible for the induction of the phase II detoxifying enzyme glutathione S-transferase (GST) activity. Up-regulation of the detoxification pathway by the phase II enzymes such as glutathione S-transferase (GST) and NAD(P)H: quinone reductase (QR) for the removal of various toxic compounds, such as carcinogens, chemotherapeutic drugs, environmental pollutants, and oxidative stress products, is one of the cellular protection mechanisms that may be anticarcinogenic.

Apoptosis Induction and Cell Cycle Arrest

Limonoids exhibit anticancer properties by inducing cell cycle arrest and inhibiting cancer cell proliferation through mechanisms such as suppressing cyclin-dependent kinases. Research has shown that limonin has an anti-breast cancer effect. It has been reported that limonin has cytotoxic effects on estrogen receptor (ER)-positive (MCF-7) and estrogen receptor (ER)-negative (MDA-MB-231) human breast cancer cells, possibly by activating a caspase-7-dependent pathway to achieve inhibition of proliferation activity.

Oncogenic Signaling Pathway Modulation

The anticancer effects of neem limonoids are mediated through the inhibition of hallmark capabilities of cancer such as cell proliferation, apoptosis evasion, inflammation, invasion, and angiogenesis. The neem limonoids have been demonstrated to target oncogenic signaling kinases and transcription factors chiefly, NF-κB, Wnt/β-catenin, PI3K/Akt, MAPK, and JAK/STAT signaling pathways.

Cholesterol Metabolism

Manners and colleagues found that limonin may lower cholesterol. The researchers showed that, when exposed to limonin, human liver cells in petri dishes produced less apolipoprotein B (apo B), a compound associated with higher cholesterol levels.

Anti-Inflammatory Mechanisms

Citrus fruits and limonoids were indicated to act by preventing heart disease, inflammation, and arteriosclerosis with their hepatoprotective, antimicrobial, neuroprotective, antioxidant, and anti-diabetic properties. The anti-inflammatory actions of limonoids are thought to involve modulation of pro-inflammatory signaling cascades, including NF-κB and related pathways, though most evidence to date is from cell-culture and animal models.

5. Scientific Evidence by Health Area

5.1 Cancer Chemoprevention

This group of secondary metabolites exhibits a wide range of biological properties, including anticancer, antibacterial, antifungal, antimalarial, and antiviral activities. Significant progress on the role of limonoids as promising candidates for cancer chemoprevention and/or therapy has been achieved in particular in recent years.

Animal evidence: Using the hamster cheek pouch model, three new limonoids (ichangensin, deoxylimonin, and obacunone) were tested for cancer chemopreventive activity. Treatments with ichangensin had no effect on tumor number or burden. In the second experiment, obacunone reduced tumor number and burden by 25 and 40%, respectively, whereas deoxylimonin reduced tumor number and burden by 30 and 50%, respectively. The results with deoxylimonin were significant (p < 0.05).

In vivo animal experiments have reported that limonin has strong anti-tumor activity—it can resist liver cancer induced by aflatoxin-B1 through the induction of heterogeneous enzymes. In addition, limonin (50 mg/kg) has excellent antioxidant and therapeutic effects on N-nitroethylenediamine (DEN)-induced hepatocarcinoma rats by suppressing lipid peroxidation (LPO) and oxidative stress-mediated free radical generation, and through modulating antioxidants' defense mechanism.

Cell culture evidence (breast cancer): A panel of 9 purified limonoids, including limonin, nomilin, obacunone, limonexic acid (LNA), isolimonexic acid (ILNA), nomilinic acid glucoside (NAG), deacetyl nomilinic acid glucoside (DNAG), limonin glucoside (LG) and obacunone glucoside (OG) as well as 4 modified compounds, were screened for their cytotoxicity on estrogen receptor (ER)-positive (MCF-7) or ER-negative (MDA-MB-231) human breast cancer cells. Among the tested limonoids, 11 limonoids exhibited cytotoxicity on MCF-7 whereas 8 limonoids showed cytotoxicity against the MDA-MB-231 cell lines. Although most of the limonoids showed anti-aromatase activity, the inhibition of proliferation was not related to the anti-aromatase activity.

Phase II enzyme induction (animal model): Female A/J mice were treated with three limonoids and a mixture in order to evaluate their effect on phase II enzymes in four different tissues. Assays for glutathione S-transferase and NAD(P)H: quinone reductase (QR) were used to evaluate induction of phase II enzymatic activity. The highest induction of GST against 1-chloro-2,4-dinitrobenzene (CDNB) was observed in stomach (whole), 58% by nomilin, followed by 25% isoobacunoic acid and 19% deacetyl nomilin. A significant induction of NAD(P)H: quinone reductase (QR) activity was observed by the limonoid mixture in stomach (200%). In addition, the deacetyl nomilin treatment group displayed an increase in QR activity in liver (183%) and intestine (22%).

Evidence strength — cancer: Based on observations of limonoids' anticancer activities in animals, new foods rich in limonoid glucosides are under development. However, clinical trials are needed to substantiate the claims in humans. As of the available literature, there are no completed large-scale randomized controlled trials in humans specifically using limonoids for cancer prevention or treatment. The existing evidence base is primarily preclinical (in vitro and animal models).

5.2 Cardiovascular Health and Cholesterol Lowering

Evaluation of the biological activity of citrus limonoids has indicated the potential of these compounds to improve human health as anticancer, cholesterol-lowering, and antiviral agents.

Cell and animal evidence: Evidence of the contribution of citrus fruits to human health was obtained in a study of the effect of orange and grapefruit juice consumption on cholesterol metabolism in rabbits. This study showed that replacing drinking water with either orange juice or grapefruit juice reduced serum LDL cholesterol levels by 43% and 32%, respectively.

Human clinical trial (registered): Although limonoids are part of the natural human diet, the dose required to provide health benefits and the risks associated with the intake of high doses by humans have not been fully studied. A USDA-sponsored study examined the metabolism, safety, lipid-lowering, and anti-inflammatory effects of limonoids. The dose of limonoids in this study was equivalent to that found in six 8-oz glasses of orange juice per day. The investigators hypothesized that limonin glucoside supplementation would reduce total cholesterol, LDL cholesterol, ratio of LDL and HDL cholesterol, number of LDL particles, and serum markers of inflammation. For the intervention period, one group consumed two beverages containing limonoids (250 mg/beverage) per day over 56 days, followed by crossover.

A human study revealed that administration of a 750-mL dose of orange juice daily to 15 human subjects with elevated serum cholesterol levels increased HDL cholesterol levels by 21%.

Evidence strength — cardiovascular: Previous studies have shown that flavonoids and limonoids from citrus, as well as unextracted citrus juices, have cholesterol-lowering properties. However, these studies typically involve whole juices that contain multiple bioactive compounds, making it difficult to attribute effects specifically to limonoids. Dedicated human clinical trials with isolated limonoids are limited. The evidence base remains preliminary, primarily from cell models, animal experiments, and small human juice-consumption studies.

5.3 Antimicrobial Activity

Citrus limonoids showed various bioactivities such as anti-tumor, antioxidative, anti-inflammatory, anti-neurological diseases, immunomodulatory, anti-insect, anti-bacterial, and antiviral activities. Limonoids exert significant antibacterial and antifungal activities. Nomilin has also been shown to inhibit HIV-1 replication by inhibiting p-24 antigen activity and protease activity in cell systems.

Evidence strength — antimicrobial: Current evidence is derived primarily from in vitro cell culture and microbial assays. Clinical trials demonstrating antimicrobial or antiviral efficacy in humans have not been identified in the reviewed literature.

5.4 Neuroprotection

In various central nervous system disorders such as epilepsy, Alzheimer's disease, and ischemia, glutamate-induced oxidative damage is a key driver to neuronal degeneration and death. In vitro studies evaluating neuroprotective activity revealed that limonoids in the genus Khaya showed potent neuroprotective effects in glutamate-induced injury in primary rat cerebellar granule neuronal cells. Further clinical studies need to be done to elucidate the mechanism via which the neuroprotective effect of limonoid is mediated, after which limonoids can then be explored as potential agents in the treatment of neurological disorders.

Several biological activities have been attributed to gedunin, including antibacterial, insecticidal, antimalarial, antiallergic, anti-inflammatory, anticancer, and neuroprotective effects.

Evidence strength — neuroprotection: All current neuroprotective evidence for limonoids is from in vitro cell models and, to a lesser extent, animal studies. No clinical trials in human populations have been identified.

5.5 Anti-Inflammatory Activity

Limonin has a wide spectrum of pharmacological effects, including anti-cancer, anti-inflammatory and analgesic, anti-bacterial and anti-virus, anti-oxidation, and liver protection properties. Neem limonoids have been demonstrated to target oncogenic signaling kinases and transcription factors chiefly, NF-κB, Wnt/β-catenin, PI3K/Akt, MAPK, and JAK/STAT signaling pathways, multiple arms of which drive inflammatory signaling.

Evidence strength — anti-inflammatory: Evidence is from cell-culture and animal models. No dedicated clinical trials in human inflammatory conditions have been identified in the reviewed literature.

5.6 Antidiabetic Activity

Over the past few decades, there has been a growing interest in studying citrus limonoids due to their diverse range of bioactivities, such as antitumor, antimicrobial, antioxidant, and antiviral properties. According to previous studies, citrus limonoids have demonstrated promising bioactivities, making them potentially valuable in the food and pharmaceutical sectors. Research in this area has extended to antidiabetic potential, involving alpha-glucosidase inhibition and related mechanisms; however, the evidence base for limonoids specifically as antidiabetic agents in humans remains at the preclinical stage.

5.7 Antifeedant and Insecticidal Activity

Limonoids possess antifeedant activity against insects. Azadirachtin from neem is perhaps the most commercially exploited limonoid in this context. Azadirachtin is a highly oxidized tetranortriterpenoid that has antifeedant and growth-regulating effects on insects and fungi. This application is well-established and commercially developed, but falls outside the direct scope of dietary supplementation for human health.

5.8 Hepatoprotective Activity

Modern pharmacological effects indicate that limonin has value in the prevention and treatment of certain diseases, including cancer, enteritis, hepatitis, hemorrhoids, osteoporosis, obesity, anaphylactic reaction, and brain aging. Hepatoprotective activity of Meliaceae limonoids has been documented in preclinical models, and pharmacological investigations carried out on limonoids isolated from different plant parts in the genus Khaya provided empirical support for some of its ethnomedicinal uses, mainly in treating liver problems.

Evidence strength — hepatoprotection: Primarily in vitro and animal data. No clinical trials have been identified.

6. Body Systems and Health Areas of Association

• Oncology/Cancer Biology: Chemoprevention, apoptosis induction, anti-proliferative activity across multiple cancer cell lines.
• Cardiovascular System: Reduction of LDL cholesterol, modulation of apolipoprotein B secretion, potential anti-inflammatory effects on endothelium.
• Immune System: Immunomodulatory effects; induction of phase II detoxifying enzymes.
• Nervous System: Preclinical neuroprotection against glutamate-induced neuronal injury; investigated in relation to Alzheimer's disease and Parkinson's disease models.
• Gastrointestinal System: Induction of detoxifying enzymes in stomach and intestinal tissues; potential anti-ulcer effects.
• Liver: Hepatoprotective effects in animal models; modulation of hepatic metabolic enzymes; complex interactions with CYP450 enzymes.
• Metabolic/Endocrine: Emerging antidiabetic evidence (alpha-glucosidase inhibition, glucose metabolism) at preclinical stage.
• Infectious Disease: In vitro antimicrobial, antifungal, and antiviral (including anti-HIV) activities.

7. Dosage Forms and Reported Dosages

Limonoids do not have established pharmacopeial monograph dosages for human supplementation. The following dosages appear specifically in published studies:

• In the USDA crossover trial (NCT02011789), subjects consumed two beverages containing limonoids (250 mg/beverage) per day — i.e., 500 mg/day total — for a 56-day metabolic period.
• The dose of limonoids in this study was described as equivalent to that found in six 8-oz glasses of orange juice per day.
• In an in vivo hepatocarcinoma rat model, limonin was administered at 50 mg/kg.
• In one human study, 750 mL of orange juice was administered daily to 15 human subjects with elevated serum cholesterol levels.

No standardized clinical dose for isolated limonoids as dietary supplements has been established by any regulatory body. Intake via normal dietary consumption of citrus fruits and their juices represents the most common route of exposure.

8. Pharmacokinetics and Bioavailability

Pharmacokinetic studies showed that limonin had low solubility, poor oral absorption, and low bioavailability, mainly due to the insoluble chemical structure of limonin and its ability to activate the activity of P-glycoprotein (P-gp). Pharmacokinetic studies have demonstrated that limonin has poor bioavailability, and the reduction, hydrolysis, and methylation are the main metabolic pathways of limonin.

The body can readily access a limonoid called limonin from citrus. The USDA team was the first to show limonin's bioavailability. The body derives limonin from a parent compound—limonin glucoside—that is present in citrus and citrus juices in about the same amount as vitamin C. This conversion from glucoside to aglycone is believed to occur during gastrointestinal processing.

In recent years, limonin has attracted considerable interest in the medicinal chemistry community owing to its promising multiple pharmacological activities and intriguing structure. However, its imprecise mechanism of action, limited water solubility, poor oral bioavailability, and complex toxicity have greatly hindered its clinical potential. Hence, studies on the combination of limonin with other drugs have been constructed to enhance therapeutic effects and bioavailability.

9. Safety Considerations and Interactions

Toxicity Findings in Preclinical Studies

Limonin has also been shown to lead to hepatotoxicity, renal toxicity, and genetic damage. Moreover, limonin also has complex impacts on hepatic metabolic enzymes. In recent years, the toxicity of limonin has also been reported. Some studies have shown that limonin has hepatorenal and genetic toxicity. These findings are derived from in vitro and animal experiments; the clinical relevance for humans at dietary exposure levels is not yet established.

Hepatic Enzyme Interactions

Limonin also has complex impacts on hepatic metabolic enzymes. Pharmacokinetic studies have demonstrated that limonin has poor bioavailability, and the reduction, hydrolysis, and methylation are the main metabolic pathways of limonin. The impact of limonoids on hepatic CYP450 enzymes is of potential clinical significance, as modulation of these enzymes could affect the metabolism of co-administered drugs. Recent findings suggest that the consumption of citrus fruits, specifically grapefruit and oroblanco, modulate both phase I and phase II metabolizing enzymes in rats.

Human Safety — Current Status

Although limonoids are part of the natural human diet, the dose required to provide health benefits and the risks associated with the intake of high doses by humans have not been fully studied. The bitterness of aglycone-form limonoids limits inadvertent high-dose intake from dietary sources. Limonoid aglycones that cause bitterness in numerous citrus fruits are converted into tasteless limonoid glucosides during fruit maturation, meaning that mature fresh fruits contain primarily the non-bitter, water-soluble glucoside forms.

Structural Determinants of Safety and Activity

The position and group of the substituents of limonin are key in affecting pharmacological activity and bioavailability. The substitution of the C-7 position of limonin has important structural characteristics, and new structural derivatives can significantly enhance anti-inflammatory, analgesic, and antimicrobial activities, and show higher water solubility to improve bioavailability.

Key Limitations and Research Gaps

Represented by limonin, the aglycones and glycosides of CLs have shown numerous pharmacological activities including anticancer, antimicrobial, antioxidant, antidiabetic, and insecticidal, among others. However, more pharmacological research is necessary to assess the safety, efficacy, and optimal dosing for human health applications. The overwhelming majority of mechanistic and efficacy data comes from cell culture and animal models. Rigorous, large-scale randomized controlled trials in humans are lacking for virtually all purported health benefits.

References

• Hasegawa S, Berhow MA. Citrus Limonoid Research: An Overview. ACS Symposium Series, 2000.
• Limonoids from Citrus: Chemistry, anti-tumor potential, and other bioactivities. Journal of Functional Foods, 2020.
• Citrus Limonoids: The Chemistry and Pharmacology of Citrus Limonoids. Molecules, 2016; PMC6273274.
• An overview on chemical aspects and potential health benefits of limonoids and their derivatives. PubMed, 2013.
• Citrus Limonoids: Analysis, Bioactivity, and Biomedical Prospects. Journal of Agricultural and Food Chemistry, 2007.
• Further studies on the anticancer activity of citrus limonoids. Journal of Agricultural and Food Chemistry, 2004.
• Limonoids and their anti-proliferative and anti-aromatase properties in human breast cancer cells. PubMed, 2012.
• Limonin: A Review of Its Pharmacology, Toxicity, and Pharmacokinetics. Molecules, 2019; PMC6832453.
• Neem Limonoids as Anticancer Agents: Modulation of Cancer Hallmarks and Oncogenic Signaling. PubMed, 2016.
• Biological Activities of Gedunin—A Limonoid from the Meliaceae Family. Molecules, 2020.
• In vivo induction of phase II detoxifying enzymes, glutathione transferase and quinone reductase by citrus triterpenoids. BMC Complementary and Alternative Medicine, 2010; PMC2954937.
• Limonin Methoxylation Influences Induction of Glutathione S-Transferase and Quinone Reductase. PMC2730739.
• Metabolism And Health Effects Of Citrus Limonoids in Hypercholesterolemic Humans. ClinicalTrials.gov NCT02011789.
• Health Benefits of Citrus Limonoids Explored. USDA Agricultural Research Service, 2005.
• Biological activities of limonoids in the Genus Khaya (Meliaceae): a review. Future Journal of Pharmaceutical Sciences, Springer, 2021.
• Limonoid — an overview. ScienceDirect Topics.
• Assessment of the in vitro anti-diabetic activity with molecular dynamic simulations of limonoids isolated from Adalia lemon peels. Scientific Reports, 2024.
• Therapeutics Role of Azadirachta indica (Neem) and Their Active Constituents in Diseases Prevention and Treatment. PMC4791507.
• Neem (Azadirachta indica): Prehistory to contemporary medicinal uses to humankind. Asian Pacific Journal of Tropical Biomedicine, 2013.
• Cloning and Characterization of Limonoid Glucosyltransferase from Kinnow Mandarin (Citrus reticulata Blanco). PMC6117989.
• Identification of Putative Genes Involved in Limonoids Biosynthesis in Citrus by Comparative Transcriptomic Analysis. Frontiers in Plant Science, 2017.
• Limonoids From the Genus Melia (Meliaceae): Phytochemistry, Synthesis, Bioactivities, Pharmacokinetics, and Toxicology. Frontiers in Pharmacology, 2021.
• A Gedunin-Type Limonoid, 7-Deacetoxy-7-Oxogedunin, from Andiroba (Carapa guianensis Aublet). PMC9655357.